Carbapenems versus other beta-lactams in treating severe infections in intensive care: A systematic review of randomised controlled trials

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 27, Issue 7, 2008, Pages 531-543

  Edwards, S J ^a,c   Clarke, M J ^b   Wordsworth, S ^a   Emmas, C E ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UK COCHRANE CENTRE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFPIROME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ABDOMINAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENETIC HETEROGENEITY; HUMAN; INFECTION; INTENSIVE CARE; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

BACTERIAL INFECTIONS; BETA-LACTAMS; HUMANS; INTENSIVE CARE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 45449118477     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-008-0472-z     Document Type: Review

References (69)

1. Department of Health (2003) Winning ways: working together to reduce healthcare associated infection in England. Department of Health, London
2. National Audit Office (2000) The management and control of hospital acquired infection in acute NHS trusts in England. The Stationery Office, London
3. Donowitz LG, Wenzel RP, Hoyt JW (1982) High risk of hospital-acquired infection in the ICU patient. Crit Care Med 10:355-357
4. Wenzel RP, Thompson RL, Landry SM et al (1983) Hospital-acquired infections in intensive care unit patients: an overview with emphasis on epidemics. Infect Control 4:371-375
5. Kollef MH, Sherman G, Ward S et al (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474
6. Rello J, Gallego M, Mariscal D et al (1997) The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Care Med 156:196-200
7. Kollef MH, Ward S (1998) The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113:412-420
8. Meehan TP, Fine MJ, Krumholz HM et al (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080-2084
9. Houck PM, Bratzler DW, Nsa W et al (2004) Timing of antibiotic administration and outcomes for Medicare patients hospitalised with community-acquired pneumonia. Arch Intern Med 164:637-644
10. Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596
11. American Thoracic Society (1995) Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 153:1711-1725
12. American Thoracic Society (2001) Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 163:1730-1754
13. American Thoracic Society (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
14. Solomkin JS, Mazuski JE, Baron EJ et al (2003) Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37:997-1005
15. Stevens DS, Bisno AL, Chambers HF et al (2005) Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41:1373-1406
16. British Thoracic Society (2004) BTS guidelines for the management of community-acquired pneumonia in adults - 2004 update. Available online at: http://www.brit-thoracic.org.uk/c2/uploads/MACAPrevisedApr04.pdf
17. Bodmann KF (2005) Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 51:227-233
18. Paul M, Silbiger I, Grozinsky S et al (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev Issue 1. Art. No.: CD003344 DOI 10.1002/14651858.CD003344.pub2
19. Craig WA, Ebert SC (1994) Antimicrobial therapy in Pseudomonas aeruginosa infections. In: Baltch AL, Smith RP (eds) Pseudomonas aeruginosa infections and treatment. Marcel Dekker, New York, pp 441-517
20. Goldstein FW (2002) Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbial Infect 8:823-825
21. Khan KS, Popay J, Kleijnen (2001) Development of a review protocol. In: Undertaking systematic reviews of research on effectiveness. CRD Report Number 4, 2nd edn. Centre for Reviews and Dissemination, York
22. Higgins JPT, Green S (eds) (2005) Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3. Wiley, Chichester, UK
23. Silagy C (1993) Developing a register of randomised controlled trials in primary care. BMJ 306:897-900
24. Chapman TM, Perry CM (2003) Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2:75-107
25. Timmers GJ, van Vuurden DG, Swart EL et al (2005) Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies. Haematologica 90:1005-1006
26. Norrby SR, Geddes AM, Shah PM (1998) Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Multicentre Study Group. J Antimicrob Chemother 42:503-509
27. BNF 52 (September 2006) Home page at: http://www.bnf.org (last accessed October 2006)
28. Occhipinti DJ, Pendland SL, Schoonover LL et al (1997) Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 41:2511-2517
29. Merck Sharp, Dohme Limited (2005) Invanz® summary of product characteristics, October 2005. Available at: http://emc.medicines.org.uk (last accessed October 2006)
30. Merck Sharp, Dohme Limited (2005) Primaxin® summary of product characteristics, October 2005. Available at: http://emc.medicines.org.uk (last accessed October 2006)
31. Hurst M, Lamb HM (2000) Meropenem: a review of its use in patients in intensive care. Drugs 59:653-680
32. Chalmers TC, Celano P, Sacks HS et al (1983) Bias in treatment assignment in controlled clinical trials. N Engl J Med 309:1358-1361
33. Schulz KF, Chalmers I, Hayes RJ et al (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412
34. Moher D, Pham B, Jones A et al (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609-613
35. Shefet D, Robenshtok E, Paul M et al (2005) Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 165:1992-2000
36. Review Manager (RevMan) version 4.2.8 for Windows [computer program] (2003) The Cochrane Collaboration, Oxford, England
37. StatsDirect Ltd. (2002) StatsDirect statistical software. StatsDirect Ltd., England. Home page at: http://www.statsdirect.com)
38. Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, Oxford
39. Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
40. Solomkin JS, Yellin AE, Rotstein OD et al (2003) Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237:235-245
41. Zanetti G, Bally F, Greub G et al (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442-3447
42. Raad II, Escalante C, Hachem RY et al (2003) Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 98:1039-1047
43. Cherif H, Björkholm M, Engervall P et al (2004) A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 36:593-600
44. Niinikoski J, Havia T, Alhava E et al (1993) Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 176:255-261
45. Klein SR, Clark K, Speth J et al (1999) A randomized, double-blind, multicenter comparison of piperacillin-tazobactam (4 g/500 mg) and imipenem/cilastatin (1 g/1 g) administered intravenously every eight hours to treat intra-abdominal infections in hospitalized patients. Presented at the 37th Annual Meeting of the Infectious Diseases Society of America (IDSA'99), Philadelphia, Pennsylvania, November 1999
46. Graham DR, Lucasti C, Málafaia O et al (2002) Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 34:1460-1468
47. Roy S, Higareda I, Angel-Muller E et al (2003) Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 11:27-37
48. Dela Pena AS, Asperger W, Köckerling F et al (2006) Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 10:567-574
49. Schmitt DV, Leitner E, Welte T et al (2006) Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 34:127-134
50. Namias N, Solomkin JS, Jensen EH et al (2007) Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 8:15-28
51. Oppenheim BA, Morgenstern GR, Chang J et al (2001) Safety and efficacy of piperacillin/tazobactam versus meropenem in the treatment of febrile neutropenia. J Infect 43:A67
52. Reich G, Cornely OA, Sandherr M et al (2005) Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Brit J Haematol 130:265-270
53. Fukushima R, Matsushima T, Kawane H et al (1986) A comparative study of MK-0787/MK0-0791 and piperacillin against respiratory tract infections. J Jpn Assoc Infect Dis 60:345-374
54. Brismar B, Malmborg AS, Tunevall G et al (1992) Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 36:2766-2773
55. Jhee SS, Gill MA, Yellin AE et al (1995) Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections. Clin Therapeu 17:126-135
56. Jaccard C, Troillet N, Harbarth S et al (1998) Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42:2966-2972
57. Marra F, Reynolds R, Stiver G et al (1998) Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 31:355-368
58. Allo MD, Bennion RS, Kathir K et al (1999) Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 65:99-104
59. Bradford PA, Testa RT, Clark K et al (1999) Randomised, double-blind comparison efficacy study of piperacillin/tazobactam (PTZ) and imipenem/cilastatin (IPM) administered intravenously q8h to treat intra-abdominal patients (IAI). Presented at the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC'99), San Francisco, California, September 1999
60. Naber KG, Savov O, Slamen HC (2002) Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 19:95-103
61. Erasmo AA, Crisostomo AC, Yan L-N et al (2004) Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg 27:227-235
62. Lipsky BA, Armstrong DG, Citron DM et al (2005) Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366:1695-1703
63. Biron P, Fuhrmann C, Kheder R et al (1997) Cefepime (CEF) vs imipenem-cilastatin (IMP) as empiric monotherapy in 400 febrile patients with short duration neutropenia. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC'97), Toronto, Ontario, Canada, September/October 1997
64. Cornely OA, Reichert D, Buchheidt D et al (2001) Three-armed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG Study III). Abstract presented at the 41st Interscience Conference on Antimicrobials and Chemotherapy (ICAAC 2001), Chicago, Illinois, December 2001
65. Tamura K, Matsuoka H, Tsukada J et al (2002) Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol 71:248-255
66. Paul M, Yahav D, Fraser A et al (2006) Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of controlled randomized trials. J Antimicrobial Chemother 57:176-189
67. Figuera A, Rivero N, Pajuelo F et al (2001) Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996). Med Clin (Barc) 116:610-611
68. Simmonds MC, Higgins JPT, Stewart LA et al (2005) Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2:209-217
69. Keating GM, Perry CM (2005) Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 65:2151-2178